As Biotechnology businesses, Exelixis Inc. (NASDAQ:EXEL) and Wave Life Sciences Ltd. (NASDAQ:WVE), are affected by contrast. This especially applies to their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis Inc.	853.83M	8.67	690.07M	2.21	10.20
Wave Life Sciences Ltd.	14.41M	100.53	146.65M	-4.86	0.00

Table 1 demonstrates Exelixis Inc. and Wave Life Sciences Ltd.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has Exelixis Inc. and Wave Life Sciences Ltd.’s net margins, return on assets and return on equity.

	Net Margins	Return on Equity	Return on Assets
Exelixis Inc.	80.82%	75.7%	66.8%
Wave Life Sciences Ltd.	-1,017.70%	-112.2%	-55%

Liquidity

The Current Ratio and Quick Ratio of Exelixis Inc. are 8.5 and 8.4 respectively. Its competitor Wave Life Sciences Ltd.’s Current Ratio is 1.9 and its Quick Ratio is 1.9. Exelixis Inc. can pay off short and long-term obligations better than Wave Life Sciences Ltd.

Analyst Recommendations

Ratings and Recommendations for Exelixis Inc. and Wave Life Sciences Ltd. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Exelixis Inc.	0	1	2	2.67
Wave Life Sciences Ltd.	0	0	0	0.00

Exelixis Inc. has a 35.60% upside potential and a consensus price target of $33.33.

Institutional & Insider Ownership

Exelixis Inc. and Wave Life Sciences Ltd. has shares held by institutional investors as follows: 77.6% and 74.4%. Insiders held 1.3% of Exelixis Inc. shares. Competitively, insiders own roughly 1.3% of Wave Life Sciences Ltd.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Exelixis Inc.	0.85%	-4.29%	14.4%	15.46%	-6.82%	14.69%
Wave Life Sciences Ltd.	14.43%	19.46%	0.82%	-12.75%	-10.64%	5.85%

For the past year Exelixis Inc. was more bullish than Wave Life Sciences Ltd.

Summary

On 11 of the 12 factors Exelixis Inc. beats Wave Life Sciences Ltd.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The companyÂ’s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

WAVE Life Sciences Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in HuntingtonÂ’s disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In HuntingtonÂ’s disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company has a research, license, and option agreement with Pfizer Inc. for the discovery, development, and commercialization of stereopure oligonucleotide therapeutics; and research collaboration with nLife Therapeutics S.L. exploring cell-specific targeting of nucleic-acid therapeutics in the central nervous system. WAVE Life Sciences Ltd. was founded in 2012 and is based in Cambridge, Massachusetts.